- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04586010
Een studie om de werkzaamheid en veiligheid van Fenebrutinib te evalueren in vergelijking met Teriflunomide bij relapsing multiple sclerose (RMS) (FENhance)
Een fase III multicenter gerandomiseerde, dubbelblinde, dubbel-dummy studie met parallelle groepen om de werkzaamheid en veiligheid van fenebrutinib te evalueren in vergelijking met teriflunomide bij volwassen patiënten met recidiverende multiple sclerose
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Buenos Aires, Argentinië, C1424
- Centro de Especialidades Neurológicas y Rehabilitación - CENyR
-
Buenos Aires, Argentinië, C1405BCH
- IME - Instituto Médico Especializado
-
Buenos Aires, Argentinië, C1182ACA
- Neurologia Infantil Buenos Aires (NIBA)
-
C. A. B. A., Argentinië, C1055AAF
- CIER
-
Rosario, Argentinië, 2000
- Diagnostico Medico Oroño
-
San Juan, Argentinië, J5400CEP
- Cer San Juan
-
San Miguel de Tucumán, Argentinië, T4000AXL
- Centro de Investigaciones Médicas Tucuman
-
-
-
-
-
Beijing, China
- Beijing Tiantan Hospital,Capital Medical University
-
Beijing, China, 100034
- Peking University First Hospital
-
Changchun, China, 130021
- the First Hospital of Jilin University
-
Changsha, China, 410008
- Xiangya Hospital Central South University
-
Chengdu, China, 610041
- West China Hospital, Sichuan University
-
Chongqing, China, 400016
- The First Affiliated Hospital, Chongqing Medical University
-
Guangzhou, China, 510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Guangzhou, China, 510260
- The second Affiliated Hospital of Guangzhou Medical University
-
Guiyang, China
- The affiliated Hospital of Guiyang Medical College
-
Kunming, China, 650021
- The First People?s Hospital of Yunnan Province
-
Shijiazhuang, China, 05000
- The Second Hospital of Hebei Medical University
-
Suzhou, China, 215031
- The First Affiliated Hospital of Soochow University
-
Taiyuan, China
- 1st Affiliated Hospital of Shanxi Medical University
-
Tianjin, China, 300052
- Tianjin Medical University General Hospital
-
Wuhan, China, 430030
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
-
Xi'an, China
- Tangdu Hospital, The Fourth Military Medical University
-
Ürümqi, China, 830000
- Xinjiang People Hospital
-
-
-
-
-
Santiago de los Caballeros, Dominicaanse Republiek, 51000
- NeuroINC
-
Santo Domingo, Dominicaanse Republiek, 10210
- Hospital Padre Billini
-
-
-
-
-
Berlin, Duitsland, 13347
- Jüdisches Krankenhaus Berlin
-
Böblingen, Duitsland, 71034
- Studienzentrum Dr. Bischof GmbH
-
Dresden, Duitsland, 01307
- Universitätsklinikum "Carl Gustav Carus", Zentrum für Klinische Neurowissenschaften
-
Giessen, Duitsland, 35385
- Universitätsklinikum Gießen und Marburg GmbH
-
Kiel, Duitsland, 24105
- Uniklinik Schleswig-Holstein
-
Stuttgart, Duitsland, 70174
- Praxis Dr. med. Andreas Kowalik, Arzt für Neurologie und Psychiatrie
-
Tübingen, Duitsland, 72076
- Universitätsklinikum Tübingen, Zentrum für Neurologie
-
Ulm, Duitsland, 89081
- Universitätsklinikum Ulm
-
Westerstede, Duitsland, 26655
- Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz
-
-
-
-
-
Helsinki, Finland, 00290
- Helsinki University Central Hospital
-
-
-
-
-
Tbilisi, Georgië, 0179
- Khechinashvili University Hospital
-
Tbilisi, Georgië, 0114
- New Hospitals
-
Tbilisi, Georgië, 0114
- Pineo Medical Ecosystem
-
Tbilisi, Georgië, 0160
- MediClab Georgia
-
Tbilisi, Georgië, 0159
- St. Michael hospital
-
-
-
-
-
Budapest, Hongarije, 1033
- Clinexpert Kft.
-
Budapest, Hongarije, 1044
- S-Medicon Egeszsegugyi Szolgaltato Kft.
-
Eger, Hongarije, 3300
- Markhot Ferenc Oktatokorhaz és Rendelointezet
-
Kistarcsa, Hongarije, 2143
- Pest Megyei Flor Ferenc Korhaz
-
Szeged, Hongarije, 6725
- Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
-
-
-
-
-
Hong Kong, Hongkong
- Pamela Youde Nethersole Eastern Hospital
-
Shatin, New Territories, Hongkong
- Prince of Wales Hospital
-
-
-
-
Apulia
-
Foggia, Apulia, Italië, 71100
- AO.U. Policlinico Riuniti Foggia
-
-
Campania
-
Naples, Campania, Italië, 80131
- AOU Seconda Università degli Studi
-
Naples, Campania, Italië, 80138
- AOU Policlinico - Università L. Vanvitelli
-
-
Emilia-Romagna
-
Parma, Emilia-Romagna, Italië, 43126
- A.O.U. di Parma
-
-
Lazio
-
Rome, Lazio, Italië, 00185
- Policlinico Umberto I
-
Rome, Lazio, Italië, 00189
- Azienda Ospedaliera Sant'Andrea
-
Rome, Lazio, Italië, 00133
- Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
-
-
Lombardy
-
Bergamo, Lombardy, Italië, 24127
- ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla
-
Milan, Lombardy, Italië, 20132
- IRCCS Ospedale San Raffaele
-
-
Piedmont
-
Mondovì (CN), Piedmont, Italië, 12084
- Ospedale Regina Montis Regalis
-
-
Sicily
-
Catania, Sicily, Italië, 95123
- AOU Policlinico V. Emanuele - P.O G. Rodolico
-
-
Veneto
-
Padova, Veneto, Italië, 35128
- Azienda Ospedaliera di Padova
-
-
-
-
-
Nairobi, Kenia, 00100
- The Aga Khan University-Kenya.
-
-
-
-
Coahuila
-
Saltillo, Coahuila, Mexico, 25050
- Clinical Research Institute Saltillo
-
-
Mexico CITY (federal District)
-
Mexico City, Mexico CITY (federal District), Mexico, 03100
- Grupo Medico de Investigacion Clinica Multidisciplinaria
-
Mexico City, Mexico CITY (federal District), Mexico, 03100
- Health Pharma Professional Research
-
-
Sinaloa
-
Culiacán, Sinaloa, Mexico, 80020
- Neurociencias Estudios Clinicos S.C.
-
-
Tlaxcala
-
Mexico, Tlaxcala, Mexico, 06726
- Hospital General de Mexico
-
-
-
-
-
Sittard-Geleen, Nederland, 6162 BG
- Zuyderland Medisch Centrum - Sittard Geleen
-
-
-
-
-
Shtip, Noord-Macedonië, 2000
- Clinical Hospital Stip
-
Skopje, Noord-Macedonië, 1000
- PHO General City Hospital 8th September Center for dialysis
-
Skopje, Noord-Macedonië, 1000
- University Clinic for Neurology - Skopje
-
-
-
-
-
Dnipro, Oekraïne, 49027
- SI USSRI of Medical and Social Problems of Disabilities of MOHU
-
Kharkiv, Oekraïne, 61068
- Ams of Ukraine
-
Kyiv, Oekraïne, 03037
- Medical Center of Private Execution First Private Clinic
-
Kyiv, Oekraïne, 02123
- Medical Center Dopomoga Plus
-
Lviv, Oekraïne, 79010
- Lviv Regional Clinical Hospital
-
Lviv, Oekraïne, 79029
- "Neurofocus" LLC
-
Odesa, Oekraïne, 65117
- Odesa Regional Clinical Hospital
-
Vinnytsi, Oekraïne, 21009
- Medical Clinical Research Center of Medical Center LLC Health Clinic
-
Zaporizhzhya, Oekraïne, 69600
- Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council
-
Zaporizhzhya, Oekraïne, 69035
- LCC "Medical center "Unimed"
-
-
KIEV Governorate
-
Vinnytsia, KIEV Governorate, Oekraïne, 21009
- Salutem Medical Center
-
-
Tavria Okruha
-
Dnipro, Tavria Okruha, Oekraïne
- Separated structural unit ?University hospital? of Dnipro State Medical University
-
-
-
-
-
Bellavista, Peru, Callao 2
- Hospital IV Alberto Sabogal Sologuren
-
La Victoria, Lima, Peru, Lima 13
- Hospital Nacional Guillermo Almenara Irigoyen
-
Lima, Peru, Lima 29
- Hospital Maria Auxiliadora
-
Lima, Peru, 15018
- Hospital Nacional Dos de Mayo
-
Lima, Peru, Lima 01
- Clinica Internacional Sede Lima
-
Pueblo Libre, Peru, Lima 21
- Clinica Centenario Peruano Japonesa
-
-
-
-
-
?ory, Polen, 44-240
- ProNeuro Centrum Medyczne
-
Bydgoszcz, Polen, 85-796
- Neurocentrum Bydgoszcz sp. z o.o
-
Katowice, Polen, 40-568
- Care Clinic
-
Krosno, Polen, 38-400
- MT Medic Krosno
-
Lodz, Polen, 90-324
- Centrum Neurologii Krzysztof Selmaj
-
Lublin, Polen, 20-492
- Rodzinne Centrum Medyczne Lubimed.pl
-
Warsaw, Polen, 02-957
- Instytut Psychiatrii i Neurologii II Klinika Neurologiczna
-
Zabrze, Polen, 41-800
- IBISMED Wielospecjalistyczne Centrum Medyczne
-
-
-
-
-
Braga, Portugal, 4710-243
- Hospital de Braga
-
Coimbra, Portugal, 3000-075
- HUC
-
Lisbon, Portugal, 1500-650
- Hospital da Luz
-
Lisbon, Portugal, 1169-050
- Hospital Santo Antonio dos Capuchos
-
Porto, Portugal, 4200-319
- Hospital de Sao Joao
-
Porto, Portugal, 4099-001
- Hospital Geral de Santo Antonio
-
Santa Maria da Feira, Portugal, 4520-211
- Centro Hospitalar Entre o Douro e Vouga E.P.E. - Hospital de São Sebastião
-
-
-
-
-
Kirov, Rusland, 610007
- Center of Cardiology and Neurology
-
Novosibirsk, Rusland, 630007
- FSBIH Siberian Regional Medical Centre of FMBA of Russia
-
-
Bashkortostan Republic
-
Ufa, Bashkortostan Republic, Rusland, 450005
- Republican clinical hospital named after G.G. Kuvatov
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, Rusland, 194291
- Leningrad Regional Clinical Hospital
-
Saint Petersburg, Sankt-Peterburg, Rusland, 197022
- Pavlov State Medical Uni
-
-
Ulyanovsk Oblast
-
Ulyanovsk, Ulyanovsk Oblast, Rusland, 432063
- Ulyanovsk Regional Clinical Hospital
-
-
-
-
-
Belgrade, Servië, 11000
- University Clinical Center of Serbia
-
-
-
-
-
Barcelona, Spanje, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, Spanje, 28034
- Hospital Ramon y Cajal
-
Madrid, Spanje, 28007
- Hospital General Universitario Gregorio Marañon
-
Madrid, Spanje, 28040
- Fundacion Jimenez Diaz
-
Madrid, Spanje, 28006
- Hospital Universitario de la Princesa
-
Málaga, Spanje, 29010
- Hospital Regional Universitario de Malaga ? Hospital General
-
Seville, Spanje, 41009
- Hospital Universitario Virgen Macarena
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spanje, 08907
- Hospital Universitari de Bellvitge
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spanje, 28223
- Hospital Quiron de Madrid
-
-
Murcia
-
EL Palmar (EL Palmar), Murcia, Spanje, 30120
- Hospital Universitario Virgen de Arrixaca
-
-
Pontevedra
-
Vigo, Pontevedra, Spanje, 36213
- Hospital Alvaro Cunqueiro
-
-
-
-
-
Mannouba, Tunesië, 2010
- Hopital Razi
-
Monastir, Tunesië, 5000
- Fattouma Bourguiba Hospital
-
Sfax, Tunesië, 3029
- Hospital Habib Bourguiba
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- University of Alabama Birmingham
-
Homewood, Alabama, Verenigde Staten, 35209
- Alabama Neurology Associates
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85032
- Center for Neurology and Spine - Phoenix - Hunt - PPDS
-
-
California
-
Carlsbad, California, Verenigde Staten, 92011
- Profound Research, LLC
-
Irvine, California, Verenigde Staten, 92697
- University of California Irvine
-
Pasadena, California, Verenigde Staten, 91106
- Quantum Clinical Research, Inc
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- University of Colorado Denver
-
Denver, Colorado, Verenigde Staten, 80209
- Mountain View Clinical Research
-
Fort Collins, Colorado, Verenigde Staten, 80528
- Advanced Neurology of Colorado, LLC
-
-
Florida
-
Maitland, Florida, Verenigde Staten, 32751
- Neurology Associates, PA; Research Department
-
-
Illinois
-
Highland Park, Illinois, Verenigde Staten, 60035
- NorthShore University HealthSystem
-
-
Indiana
-
Fort Wayne, Indiana, Verenigde Staten, 46805
- Fort Wayne Neurological Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70810
- The NeuroMedical Center
-
Shreveport, Louisiana, Verenigde Staten, 71103
- Ochsner LSU Health
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins University School Of Medicine; Outpatient Center
-
-
Massachusetts
-
Worcester, Massachusetts, Verenigde Staten, 01655
- University of Massachusetts Medical School
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Henry Ford Health System
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Teaneck, New Jersey, Verenigde Staten, 07666
- Holy Name Hospital; Institute For Clinical Research
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87131
- University of New Mexico; MS Specialty Clinic
-
-
Ohio
-
Centerville, Ohio, Verenigde Staten, 45459
- Miami Valley Hospital South; Dayton Physician's Office
-
Columbus, Ohio, Verenigde Staten, 43214
- OhioHealth
-
Columbus, Ohio, Verenigde Staten, 43235
- The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- Oklahoma Medical Research Foundation; MS Center of Excellence
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Verenigde Staten, 18015
- St. Luke's University Health network
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29605
- Premier Neurology
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37920
- New Orleans Center for Clinical Research
-
-
Texas
-
Plano, Texas, Verenigde Staten, 75024
- North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic
-
Sherman, Texas, Verenigde Staten, 75092
- Texas Institute for Neurological Disorders
-
-
Virginia
-
Vienna, Virginia, Verenigde Staten, 22182
- Multiple Sclerosis Center of Greater Washington
-
-
Washington
-
Kirkland, Washington, Verenigde Staten, 98034
- Evergreen MS Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53215
- Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders
-
-
-
-
-
Bern, Zwitserland, 3010
- Inselspital Bern Medizin Neurologie
-
Lugano, Zwitserland, 6903
- Ospedale Regionale di Lugano - Civico
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening
- A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria
- Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in < 240 seconds
- Ability to perform the Timed 25-Foot Walk Test (T25FWT) in < 150 seconds
- For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs
- For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm
OLE Inclusion Criteria:
- Completed the DBT phase of the study (remaining on study treatment; no other disease-modifying therapy (DMT) administered) and who, in the opinion of the investigator, may benefit from treatment with fenebrutinib
- Participants randomized to the teriflunomide treatment arm during the DBT phase must undergo the accelerated teriflunomide elimination procedure (ATEP) prior to the first administration of open-label fenebrutinib
- For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs
- For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm
Exclusion Criteria:
- Disease duration of > 10 years from the onset of symptoms and an EDSS score at screening < 2.0
- Female participants who are pregnant or breastfeeding, or intending to become pregnant
- Male participants who intend to father a child during the study
- A diagnosis of primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (SPMS)
- Any known or suspected active infection at screening, including but not limited to a positive screening test for hepatitis B (HBV) and hepatitis C (HCV), an active or latent or inadequately treated infection with tuberculosis (TB), a confirmed or suspected progressive multifocal leukoencephalopathy (PML)
- History of cancer including hematologic malignancy and solid tumors within 10 years of screening
- Known presence of other neurological disorders, that could interfere with the diagnosis of MS or assessments of efficacy or safety during the study and clinically significant cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal (GI) disease
- Rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
- Hypoproteinemia
- Acute liver disease
- Chronic liver disease unless considered stable for > 6 months
- Presence of cirrhosis (Child-Pugh Class A, B, or C) or Gilbert's Syndrome
- Participants with significantly impaired bone marrow function or significant anemia, leukopenia, neutropenia or thrombocytopenia
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- History of alcohol or other drug abuse within 12 months prior to screening
- History of or currently active primary or secondary (non-drug-related) immunodeficiency, including known history of human immunodeficiency virus (HIV) infection
- Inability to complete an MRI scan
- Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to screening (inhaled and topical corticosteroids are allowed)
- Receipt of a live-attenuated vaccine within 6 weeks prior to randomization
- Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate washout period
OLE Exclusion Criteria:
- Acute liver disease
- Chronic liver disease unless considered stable for > 6 months
- Cirrhosis (Child-Pugh Class A, B, or C)
- Gilbert's syndrome
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Fenebrutinib
Participants will receive oral (PO) fenebrutinib, with teriflunomide-matching placebo. |
Participants will receive fenebrutinib. Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo. |
|
Actieve vergelijker: Teriflunomide
Participants will receive PO teriflunomide, with fenebrutinib-matching placebo in a blinded fashion. |
Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo. Participants will receive teriflunomide. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Geannualiseerd terugvalpercentage (ARR)
Tijdsspanne: Minimaal 96 weken
|
Minimaal 96 weken
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Tijd tot begin van samengestelde 12 weken durende bevestigde invaliditeitsprogressie (cCDP12)
Tijdsspanne: Minimaal 96 weken
|
Minimaal 96 weken
|
|
Tijd tot aanvang van samengestelde 24 weken durende bevestigde invaliditeitsprogressie (cCDP24)
Tijdsspanne: Minimaal 96 weken
|
Minimaal 96 weken
|
|
Tijd tot aanvang van 12 weken durende bevestigde invaliditeitsprogressie (CDP12)
Tijdsspanne: Minimaal 96 weken
|
Minimaal 96 weken
|
|
Tijd tot aanvang van 24 weken durende bevestigde invaliditeitsprogressie (CDP24)
Tijdsspanne: Minimaal 96 weken
|
Minimaal 96 weken
|
|
Plasmaconcentraties van Fenebrutinib op gespecificeerde tijdstippen
Tijdsspanne: Tot 4,5 jaar
|
Tot 4,5 jaar
|
|
Tijd tot het begin van de composiet van 12 weken bevestigde progressie onafhankelijk van terugvalactiviteit (CPIRA12)
Tijdsspanne: Minimaal 96 weken
|
Minimaal 96 weken
|
|
Percentage van deelnemers met bijwerkingen (AEs)
Tijdsspanne: Tot 4,5 jaar
|
Tot 4,5 jaar
|
|
Total Number of T1 Gadolinium Enhancing (Gd+) Lesions, New and/or Enlarging T2-weighted Lesions, as Detected by Magnetic Resonance Imaging (MRI)
Tijdsspanne: Baseline, Weeks 12, 24, 48 and 96
|
Baseline, Weeks 12, 24, 48 and 96
|
|
Percentage Change in Total Brain Volume From Week 24 as Assessed by MRI
Tijdsspanne: From Week 24 to Week 96
|
From Week 24 to Week 96
|
|
Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT) Score
Tijdsspanne: Minimum of 96 weeks
|
Minimum of 96 weeks
|
|
Change in Participant-reported Physical Impacts of Multiple Sclerosis (MS), as Measured by the Multiple Sclerosis Impact Scale (29-item), Version 2 (MSIS-29) Physical Scale
Tijdsspanne: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96
|
Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96
|
|
Percent Change From Baseline to Week 48 in the Concentration of Blood Neurofilament Light Chain (NfL)
Tijdsspanne: Baseline, Week 48
|
Baseline, Week 48
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Trials, Hoffmann-La Roche
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- GN41851
- 2019-004857-10 (EudraCT-nummer)
- 2019 (Subsidie/contract van de Amerikaanse NIH)
- 2022-502609-14-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .